In this podcast, you will hear how Gilead designed, developed and obtained emergency-use authorization and full approval for remdesivir as treatment of COVID-19 in record time, plus the new capabilities they built to do so, the role of real world data and communicating with regulators. This session is from the 2021 DPHARM conference.
For more information on DPHARM: Disruptive Innovations to Modernize Clinical Research, visit DPHARMconference.com.
Matthew Bryant, MBA
Head of Technology & Innovation Global Development and Clinical Operations GileadGilead